REG - Venture Life Group - Director Dealings

Venture LifeAnnouncement

19/05/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250519:nRSS1361Ja&default-theme=true

RNS Number : 1361J  Venture Life Group PLC  19 May 2025

19(th) May  2025

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director Dealings

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, announces that the Board
has approved a further eight month extension of the timeline in which Mr
Jeremy Randall may exercise the 483,333 share options granted to him on 5(th)
November 2013 such that these options will now lapse on 31(st) December 2025.

The extension ensures the alignment with the Company's long-term strategic
objectives and continuity of leadership during a period of active
transformation and growth. As at the time of this announcement, Mr Randall
owns 1.72% of the issued share capital of VLG and holds 2,483,333 options.

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7720 0500
 Stephen Keys / George Lawson (Corporate Finance)

 Michael Johnson (Sales)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The
Netherlands and Sweden, the Group's product portfolio includes Balance Activ
in the area of women's intimate healthcare, Earol® supporting ENT care, Lift
and Glucogel product ranges for energy and glucose management and
hypoglycaemia, the Health and Her product range supporting the hormonal
lifecycle, the UltraDEX and Dentyl oral care product ranges, products for
fungal infections and proctology, and dermo-cosmetics for addressing the signs
of ageing.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples and are sold in over 90 countries worldwide. In the UK and The
Netherlands these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations
in Italy and Sweden, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBVLLFEELXBBF